Relationship between KRAS mutational status and tumoral variables measured in primary tumors.

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status

Libbrecht, Louis
Baldin, Paméla
Dekairelle, Anne-France
Mourin, Anne

January 2018

Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...

KRAS mutational status in the primary tumor according to metastatic site (whole series of 230 patients).

Paloma Cejas (368528)
Miriam López-Gómez (368529)
Cristina Aguayo (368530)
Rosario Madero (175498)
Javier de Castro Carpeño (368531)
Cristóbal Belda-Iniesta (368532)
Jorge Barriuso (167599)
Víctor Moreno García (368535)
Javier Larrauri (368538)
Rocío López (5653630)
Enrique Casado (368541)
Manuel Gonzalez-Barón (5653633)
Jaime Feliu (368543)

February 2013

KRAS mutational status in the primary tumor according to metastatic site (whole series of ...

Correlation between percentage of KRAS mutation in tumor cells and disease control rate.

Shaorong Yu (432172)
Xia Xiao (432173)
Jianwei Lu (432174)
Xiaoping Qian (127213)
Baorui Liu (139440)
Jifeng Feng (432175)

July 2013

Correlation between percentage of KRAS mutation in tumor cells and disease control rate.</p

Correlations between SUVmax of primary tumors and EGFR and KRAS mutation status.

Kazuya Takamochi (440443)
Kaoru Mogushi (386778)
Hideya Kawaji (13861)
Kota Imashimizu (3934688)
Mariko Fukui (3934694)
Shiaki Oh (440445)
Masayoshi Itoh (15728)
Yoshihide Hayashizaki (3101)
Weijey Ko (3934691)
Masao Akeboshi (3934685)
Kenji Suzuki (157178)

April 2017

(A) Box plot of SUVmax of primary tumors according to EGFR and KRAS muta...

KRAS mutation in adenoma and carcinoma components and clinicopathologic features.

Hyoun Wook Lee (12068806)
Boram Song (13767111)
Kyungneun Kim (13767114)

September 2022

KRAS mutation in adenoma and carcinoma components and clinicopathologic features.</p

Relationship of Overall Survival with presence of KRAS mutation in cases of Intrahepatic CCA.

Chaitanya R. Churi (678656)
Rachna Shroff (678657)
Ying Wang (11406)
Asif Rashid (678658)
HyunSeon C. Kang (678659)
Jacqueline Weatherly (678660)
Mingxin Zuo (678661)
Ralph Zinner (524306)
David Hong (341495)
Funda Meric-Bernstam (478258)
Filip Janku (160679)
Christopher H. Crane (678662)
Lopa Mishra (117813)
Jean-Nicholas Vauthey (678663)
Robert A. Wolff (678664)
Gordon Mills (499661)
Milind Javle (510872)

December 2014

Relationship of Overall Survival with presence of KRAS mutation in cases of Intrahepatic C...

KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.

Peter Jo
Markus Bernhardt
Manuel Nietert
Alexander König
Azadeh Azizian
Markus A Schirmer
Marian Grade
Julia Kitz
Kirsten Reuter-Jessen
Michael Ghadimi
Philipp Ströbel
Hans-Ulrich Schildhaus
Jochen Gaedcke

January 2020

IntroductionOncogenic mutation within the KRAS gene represents a negative predictor for treatment re...

Multivariate logistic regression model associations between patient, tumor and KRAS or BRAFV600E mutation status.

Wenbin Li (92586)
Wenxue Zhi (749577)
Shuangmei Zou (749578)
Tian Qiu (156003)
Yun Ling (178318)
Ling Shan (155985)
Susheng Shi (749579)
Jianming Ying (155982)

June 2015

CI = confidence interval; pMMR = proficient mismatch repair; OR = odds ratio.Multivariate ...

Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.

MIGLIO, Umberto
GENTILLI, Sergio
ALABISO, Oscar
BOLDORINI, Renzo Luciano
Mezzapelle R
Paganotti A
Allegrini S
Veggiani C
Antona J
Monga G

January 2013

Mutation analysis of KRAS is needed before starting treatment with anti-EGFR monoclonal antibodies i...

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

Knijn, N.
Mekenkamp, L.
Klomp, M.
Vink-Borger, M.E.
Tol, J.
Teerenstra, S.
Meijer, J.W.
Tebar, M.
Riemersma, S.
Krieken, J.H. van
Punt, C.J.A.
Nagtegaal, I.D.

January 2011

BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth f...

Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.

MIGLIO, Umberto
GENTILLI, Sergio
ALABISO, Oscar
BOLDORINI, Renzo Luciano
Mezzapelle R
Paganotti A
Allegrini S
Veggiani C
Antona J
Monga G

January 2013

Mutation analysis of KRAS is needed before starting treatment with anti-EGFR monoclonal antibodies i...

Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status.

Libbrecht, Louis
Baldin, Pamela
Dekairelle, Anne-France
Jouret-Mourin, Anne

August 2018

Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status

Libbrecht, Louis
Baldin, Paméla
Dekairelle, Anne-France
Mourin, Anne

January 2018

Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...

KRAS mutational status in the primary tumor according to metastatic site (whole series of 230 patients).

Paloma Cejas (368528)
Miriam López-Gómez (368529)
Cristina Aguayo (368530)
Rosario Madero (175498)
Javier de Castro Carpeño (368531)
Cristóbal Belda-Iniesta (368532)
Jorge Barriuso (167599)
Víctor Moreno García (368535)
Javier Larrauri (368538)
Rocío López (5653630)
Enrique Casado (368541)
Manuel Gonzalez-Barón (5653633)
Jaime Feliu (368543)

February 2013

KRAS mutational status in the primary tumor according to metastatic site (whole series of ...

Correlation between percentage of KRAS mutation in tumor cells and disease control rate.

Shaorong Yu (432172)
Xia Xiao (432173)
Jianwei Lu (432174)
Xiaoping Qian (127213)
Baorui Liu (139440)
Jifeng Feng (432175)

July 2013

Correlation between percentage of KRAS mutation in tumor cells and disease control rate.</p

Correlations between SUVmax of primary tumors and EGFR and KRAS mutation status.

Kazuya Takamochi (440443)
Kaoru Mogushi (386778)
Hideya Kawaji (13861)
Kota Imashimizu (3934688)
Mariko Fukui (3934694)
Shiaki Oh (440445)
Masayoshi Itoh (15728)
Yoshihide Hayashizaki (3101)
Weijey Ko (3934691)
Masao Akeboshi (3934685)
Kenji Suzuki (157178)

April 2017

(A) Box plot of SUVmax of primary tumors according to EGFR and KRAS muta...

KRAS mutation in adenoma and carcinoma components and clinicopathologic features.

Hyoun Wook Lee (12068806)
Boram Song (13767111)
Kyungneun Kim (13767114)

September 2022

KRAS mutation in adenoma and carcinoma components and clinicopathologic features.</p

Relationship of Overall Survival with presence of KRAS mutation in cases of Intrahepatic CCA.

Chaitanya R. Churi (678656)
Rachna Shroff (678657)
Ying Wang (11406)
Asif Rashid (678658)
HyunSeon C. Kang (678659)
Jacqueline Weatherly (678660)
Mingxin Zuo (678661)
Ralph Zinner (524306)
David Hong (341495)
Funda Meric-Bernstam (478258)
Filip Janku (160679)
Christopher H. Crane (678662)
Lopa Mishra (117813)
Jean-Nicholas Vauthey (678663)
Robert A. Wolff (678664)
Gordon Mills (499661)
Milind Javle (510872)

December 2014

Relationship of Overall Survival with presence of KRAS mutation in cases of Intrahepatic C...

KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.

Peter Jo
Markus Bernhardt
Manuel Nietert
Alexander König
Azadeh Azizian
Markus A Schirmer
Marian Grade
Julia Kitz
Kirsten Reuter-Jessen
Michael Ghadimi
Philipp Ströbel
Hans-Ulrich Schildhaus
Jochen Gaedcke

January 2020

IntroductionOncogenic mutation within the KRAS gene represents a negative predictor for treatment re...

Multivariate logistic regression model associations between patient, tumor and KRAS or BRAFV600E mutation status.

Wenbin Li (92586)
Wenxue Zhi (749577)
Shuangmei Zou (749578)
Tian Qiu (156003)
Yun Ling (178318)
Ling Shan (155985)
Susheng Shi (749579)
Jianming Ying (155982)

June 2015

CI = confidence interval; pMMR = proficient mismatch repair; OR = odds ratio.Multivariate ...

Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.

MIGLIO, Umberto
GENTILLI, Sergio
ALABISO, Oscar
BOLDORINI, Renzo Luciano
Mezzapelle R
Paganotti A
Allegrini S
Veggiani C
Antona J
Monga G

January 2013

Mutation analysis of KRAS is needed before starting treatment with anti-EGFR monoclonal antibodies i...

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

Knijn, N.
Mekenkamp, L.
Klomp, M.
Vink-Borger, M.E.
Tol, J.
Teerenstra, S.
Meijer, J.W.
Tebar, M.
Riemersma, S.
Krieken, J.H. van
Punt, C.J.A.
Nagtegaal, I.D.

January 2011

BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth f...

Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.

MIGLIO, Umberto
GENTILLI, Sergio
ALABISO, Oscar
BOLDORINI, Renzo Luciano
Mezzapelle R
Paganotti A
Allegrini S
Veggiani C
Antona J
Monga G

January 2013

Mutation analysis of KRAS is needed before starting treatment with anti-EGFR monoclonal antibodies i...

Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status.

Libbrecht, Louis
Baldin, Pamela
Dekairelle, Anne-France
Jouret-Mourin, Anne

August 2018

Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

SANTINI D
LOUPAKIS F
VINCENZI B
FLORIANI I
STASI I
CANESTRARI E
RULLI E
MALTESE PE
ANDREONI, FRANCESCA
MASI G
GRAZIANO F
BALDI GG
SALVATORE L
RUSSO A
PERRONE G
TOMMASINO MR
MAGNANI, MAURO
FALCONE A
TONINI G
RUZZO, ANNAMARIA

January 2008

Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuxi...

Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status

Libbrecht, Louis
Baldin, Paméla
Dekairelle, Anne-France
Mourin, Anne

January 2018

Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessme...

Relationship between <i>KRAS</i> mutational status and tumoral variables measured in primary tumors.

Abstract

Extracted data

Relationship between <i>KRAS</i> mutational status and tumoral variables measured in primary tumors.

Abstract

Extracted data

Related items

Related items